MasterSwitch Bio

About

MasterSwitch Bio is a joint spinout of the University of Pittsburgh and the University of Pennsylvania, co-founded by 2023 Nobel Prize laureate in Physiology or Medicine Dr. Drew Weissman. The Company has developed a modified mRNA therapy targeting Hepatocyte Nuclear Factor-4 alpha (HNF4α), the master transcriptional regulator of hepatic function, for the treatment of End Stage Liver Disease with cirrhosis. In multiple cirrhotic disease models, upregulation of HNF4α restores expression of downstream proteins critical to hepatocyte health, including those governing lipid metabolism, albumin synthesis, and coagulation, thereby restoring hepatic function.